Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vaccine injury compensation

Executive Summary

House Government Reform/Criminal Justice, Drug Policy & Human Resources Subcommittee will hold a hearing Sept. 17 to discuss the Vaccine Injury Compensation Program. Invited witnesses include VICP Director Thomas Balbier, an un-named medical expert on vaccine injuries, a lawyer involved in vaccine injury litigation and families of those allegedly harmed. At an Aug. 3 hearing of the full committee, Subcommittee Chairman Mica (R-Fla.) requested that Surgeon General David Satcher, MD/PhD, submit recommendations to his staff on potential legislation to allocate VICP funds for vaccine safety research (1"The Pink Sheet" Aug. 9, p. 14)

You may also be interested in...

Vaccine Comp Surplus Should Go To Increased Safety Research, HHS Says

HHS would like to use a portion of the $1.4 bil. Vaccine Injury Compensation Program to fund studies of vaccine safety and adverse events.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts